NR1H4 and metabolic dysfunction-associated steatohepatitis: Other drugs with known beneficial effects on NASH (pioglitazone) or with significant effects in phase 2 (GLP-1RA) or 3 (FXR agonists) trial indicate the key role of gut-liver axis alterations in promoting the progression of NAFLD to NASH.